[CAS NO. 501-94-0] Tyrosol
PRODUCTS SPECIFICATIONS [501-94-0]
DESCRIPTION [501-94-0]
Overview
| MDL | MFCD00002902 |
|---|---|
| Molecular Weight | 138.16 |
| Molecular Formula | C8H10O2 |
| SMILES | OCCC1=CC=C(O)C=C1 |
1 Publications Citing Use of MCE
Summary
IC50 & Target
|
Microbial Metabolite |
Human Endogenous Metabolite |
In Vitro
Tyrosol (1.6 mM) significantly increases the cell viability of cultured astrocytes exposed to oxygen glucose deprivation (OGD)
[1]
.
Tyrosol (1.6 mM) attenuates the released TNF-α and IL-6 level from astrocyte via regulating Janus N-terminal kinase (JNK)
[1]
.
The reduction of cytokines from astrocyte might be due to its inhibition of astrocyte activation and regulation of STAT3 signaling pathway since Tyrosol (1.6 mM) attenuates the expression level of GFAP (glial fibrillary acidic protein) and the phosphorylation of STAT3
[1]
.
Tyrosol prevents the degradation of IκBα and the increase of IκBα phosphorylation in astrocytes exposed to OGD, which leads to the suppression of NF-κB function during ischemia
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Sub-plantar injection of carrageenan causes a noticeable increase in paw thickness, reaching a peak after 2 h post-injection. This effect is reduced when Tyrosol (0.5 mg/kg) or Tyrosol-sulphate is injected prior to the treatment with carrageenan. Similar AUC values for paw oedema are obtained after the administration of Tyrosol at a dose of 0.5 mg/kg and Tyrosol-sulphate at a dose of 0.1 mg/kg.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02783989 | Parc de Salut Mar |
Cardiovascular Disease
|
January 20, 2016 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 723.80 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 7.2380 mL | 36.1899 mL | 72.3798 mL |
| 5 mM | 1.4476 mL | 7.2380 mL | 14.4760 mL |
| 10 mM | 0.7238 mL | 3.6190 mL | 7.2380 mL |
References
- [1] Luo G, et al. Tyrosol attenuates pro-inflammatory cytokines from cultured astrocytes and NF-κB activation in in vitro oxygen glucose deprivation. Neurochem Int. 2018 Dec;121:140-145.
- [2] Muriana FJG, et al. Tyrosol and its metabolites as antioxidative and anti-inflammatory molecules in human endothelial cells. Food Funct. 2017 Aug 1;8(8):2905-2914.
Synonyms